Want to connect with CatalisIA?
Join organizations building the agentic web. Get introductions, share updates, and shape the future of .agent.
Is this your company?
Claim this profile to update your info, add products, and connect with the community.
CatalisIA is an active participant in the vertical AI agent layer, specifically within the healthcare sector. Their product, ADAM, is a practical application of a conversational agent that performs autonomous tasks such as monitoring treatment adherence, sending dynamic reminders, and reporting clinical data back to medical professionals.
For builders in the agent ecosystem, CatalisIA is a case study in effective distribution and verticalization. They demonstrate how an agent can be deployed on existing surfaces like WhatsApp to achieve high engagement in a regulated industry. By using "multiple reasoning engines" and focusing on interoperability with legacy health systems, they are solving the integration challenges that often prevent AI agents from moving from experimental tools to enterprise-grade utilities. Their work with the public sector and global pharma companies highlights the potential for agents to manage high-stakes, long-term human interactions that were previously too resource-intensive to automate.
Medical adherence is one of the most persistent hurdles in chronic disease management. When patients fail to follow prescribed treatment regimens, health outcomes decline and healthcare costs rise. CatalisIA addresses this specific gap by deploying conversational AI agents designed to guide patients through their treatment journeys. Based in Buenos Aires, Argentina, the company focuses on the intersection of large language models and regulated healthcare environments.
At the center of CatalisIA’s offering is ADAM, an acronym for Asistente Digital de Adherencia Médica. Unlike general-purpose health bots, ADAM is designed as a specialized agent that operates within a structured medical context. It provides personalized medication reminders, answers questions about treatments in real time, and facilitates a continuous feedback loop between the patient and their physician. This continuous monitoring is intended to reduce the information vacuum that typically exists between scheduled medical appointments.
The choice of WhatsApp as the primary user interface is a calculated move to meet patients where they already communicate. In many regions, particularly in Latin America, WhatsApp is the dominant communication tool across all demographics. By building their agent on top of this platform, CatalisIA avoids the "app fatigue" that often leads to low adoption rates for proprietary health monitoring applications. The interface allows for natural language interactions, making the technology accessible to patients who might struggle with traditional digital health portals.
Technically, the platform relies on multiple reasoning engines to process different formats of communication and ensure the agent stays within the bounds of medically relevant information. This multi-engine approach allows the system to receive and interpret patient inputs, translate them into actionable data for doctors, and trigger appropriate responses or alerts. The company emphasizes interoperability, stating that the platform is designed to connect with various health software systems, which is a requirement for enterprise adoption in the pharmaceutical and insurance sectors.
CatalisIA has secured partnerships with several major pharmaceutical companies, including GSK, Elea, and Cassará. These collaborations suggest a business model where the technology is provided as a value-added service for patients prescribed specific medications. By helping patients stay on their treatments, pharmaceutical companies see better performance from their products, and patients receive better care outcomes.
One of the more specific applications of the technology involves a project focused on Chagas disease, a significant health challenge in parts of Latin America. In collaboration with the Ministry of Health of the City of Buenos Aires, CatalisIA deployed a conversational platform to help individuals with Chagas maintain treatment adherence. This use case demonstrates the agent's ability to handle the complexities of long-term care for infectious and chronic conditions in a public health setting. While the company utilizes technologies from providers like OpenAI, its value is in the vertical application layer, ensuring AI agents operate safely and effectively within the constraints of medical regulation.
Asistente Digital de Adherencia Médica que acompaña a los pacientes vía WhatsApp.
CatalisIA is hiring
You've explored CatalisIA.
Join organizations building the agentic web.